Zilu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zilu Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Anke Xie
Affiliations Yunnan Innovation Institute of Beihang University, Kunming, China, Yunnan Key Laboratory of Blockchain Application Technology, Kunming, China
1 shared publicationCanzhen Yang
Affiliation Neurology Department of Yan’an Hospital Affiliated to Kunming Medical University, Kunming, China
1 shared publicationChunyan Zhao
Affiliation Neurology Department of Yan’an Hospital Affiliated to Kunming Medical University, Kunming, China
1 shared publicationHaiyan Guo
Affiliations Central Laboratory, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, China, Yunnan Key Laboratory of Tumor Immunological Prevention and Control, Kunming, China Precision Medicine Center, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, China
1 shared publication- Kai Hu
Affiliations Yunnan Innovation Institute of Beihang University, Kunming, China, Yunnan Key Laboratory of Blockchain Application Technology, Kunming, China, Institute of Computer Architecture (ICA), Beihang University, Beijing, China
1 shared publication Qingyun Li
Affiliation Neurology Department of Yan’an Hospital Affiliated to Kunming Medical University, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 2 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325050
AD-GCN: A novel graph convolutional network integrating multi-omics data for enhanced Alzheimer’s disease diagnosis
Alzheimer’s disease (AD) etiology is complex, influenced by demographic risk factors such as age, sex, and educational level, alongside multi-omics factors derived from genomics, transcriptomics, and epigenomics. Advancements in multi-omics technology present both challenges and opportunities for AD diagnosis, enabling a more comprehensive understanding of the complex interactions among contributing factors, with the goal of improving diagnostic accuracy. To address this challenge, we propose a novel feature fusion approach in this study, AD-GCN, which integrates multi-omics data and their interaction networks to achieve more precise diagnosis and analysis of AD. In this study, we applied polygenic risk score and random forest algorithms for feature selection on genetic variation and methylation data. We then developed an AD-GCN for both multi-omics and single-omics classification tasks and compared its performance with that of machine learning ensemble methods. The experimental results demonstrated that multi-omics classification significantly outperformed single-omics classification, with AD-GCN surpassing the machine-learning ensembles. These findings highlight AD-GCN’s strong potential to enhance AD diagnosis and improve accuracy in differentiating disease stages by integrating interactions across omics data, laying a solid foundation for the development of more precise and personalized AD diagnostic models.
- 2 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325050
Open AccessAD-GCN: A novel graph convolutional network integrating multi-omics data for enhanced Alzheimer’s disease diagnosis
Alzheimer’s disease (AD) etiology is complex, influenced by demographic risk factors such as age, sex, and educational level, alongside multi-omics factors derived from genomics, transcriptomics, and epigenomics. Advancements in multi-omics technology present both challenges and opportunities for AD diagnosis, enabling a more comprehensive understanding of the complex interactions among contributing factors, with the goal of improving diagnostic accuracy. To address this challenge, we propose a novel feature fusion approach in this study, AD-GCN, which integrates multi-omics data and their interaction networks to achieve more precise diagnosis and analysis of AD. In this study, we applied polygenic risk score and random forest algorithms for feature selection on genetic variation and methylation data. We then developed an AD-GCN for both multi-omics and single-omics classification tasks and compared its performance with that of machine learning ensemble methods. The experimental results demonstrated that multi-omics classification significantly outperformed single-omics classification, with AD-GCN surpassing the machine-learning ensembles. These findings highlight AD-GCN’s strong potential to enhance AD diagnosis and improve accuracy in differentiating disease stages by integrating interactions across omics data, laying a solid foundation for the development of more precise and personalized AD diagnostic models.